Adamis Pharmaceuticals Corporation Interest Expense 2011-2026 | ADMP

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Adamis Pharmaceuticals Corporation

2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	-	4.92 K	123 K	158 K	231 K	214 K	-	372 K	2.33 M	35.4 K	744 K

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
2.33 M	4.92 K	469 K

Quarterly Interest Expense Adamis Pharmaceuticals Corporation

2023-Q3	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
29.5 K	-113 K	-	278 K	-	-440 K	-	1.86 K	2.9 K	1.88 K	-	1.72 K	32.9 K	38.3 K	-	21.9 K	23 K	24 K	-	30.7 K	51.4 K	50.7 K	-	52.6 K	59.4 K	67.5 K	-	70.2 K	72.4 K	-	-	-	-	-	-	371 K	226 K	145 K	5.3 M	2.78 M	3.18 M	-	845 K	1.72 M	874 K	-	2.61 K	32.7 K	30.1 K	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
5.3 M	-440 K	481 K

Interest Expense of other stocks in the Drug manufacturers industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
Assertio Holdings ASRT	2.78 M	$ 18.03	0.06 %	$ 115 M	USA
Agile Therapeutics AGRX	1.42 M	-	10.11 %	$ 58.2 M	USA
AcelRx Pharmaceuticals ACRX	1.12 M	-	7.5 %	$ 6.35 M	USA
Aerie Pharmaceuticals AERI	-27.9 M	-	-	$ 754 M	USA
Catalent CTLT	-4 M	-	-	$ 11.5 B	USA
DURECT Corporation DRRX	2.24 M	-	-	$ 50.1 M	USA
Alimera Sciences ALIM	10.2 M	-	-	$ 142 M	USA
Athenex ATNX	25.8 M	-	-23.39 %	$ 1.76 M	USA
Eagle Pharmaceuticals EGRX	4.04 M	-	-39.89 %	$ 27.7 M	USA
Endo International plc ENDP	350 M	-	-	$ 28.9 M	Irlanda
Avadel Pharmaceuticals plc AVDL	13 M	-	-	$ 2.06 B	France
Evoke Pharma EVOK	500 K	-	-	$ 36.6 M	USA
Cumberland Pharmaceuticals CPIX	606 K	$ 3.16	2.27 %	$ 44.4 M	USA
Relmada Therapeutics RLMD	5.15 M	$ 7.41	1.65 %	$ 293 M	USA
HEXO Corp. HEXO	20.1 M	-	2.45 %	$ 38.1 M	Canada
Sundial Growers SNDL	81 K	$ 1.37	-3.87 %	$ 3.37 M	Canada
Bausch Health Companies BHC	-28 M	$ 5.61	0.18 %	$ 2.05 B	Canada
Harrow Health HROW	47 K	$ 36.59	1.84 %	$ 1.35 B	USA
Canopy Growth Corporation CGC	74.6 M	$ 1.02	-2.38 %	$ 110 M	Canada
Tilray TLRY	46.6 M	$ 6.41	-2.51 %	$ 3.96 B	Canada
Neoleukin Therapeutics NLTX	12 K	-	-	$ 193 M	Canada
Jupiter Wellness JUPW	152 K	-	-	$ 33.6 M	USA
Lannett Company LCI	58 M	-	1.15 %	$ 7.11 M	USA
Veru VERU	862 K	$ 2.38	-	$ 321 M	USA
Viatris VTRS	573 M	$ 13.52	0.33 %	$ 16.2 B	USA
Evolus EOLS	-539 K	$ 4.33	1.41 %	$ 279 M	USA
Emergent BioSolutions EBS	87.9 M	$ 8.0	0.5 %	$ 410 M	USA
Organogenesis Holdings ORGO	20 K	$ 2.38	-0.21 %	$ 313 M	USA
Pacira BioSciences PCRX	-373 K	$ 24.14	1.47 %	$ 1.12 B	USA
PetIQ PETQ	38.3 M	-	1.64 %	$ 400 M	USA
ProPhase Labs PRPH	764 K	-	-	$ 5.07 M	USA
Radius Health RDUS	18.3 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	9.96 M	-	-4.76 %	$ 65.3 M	USA
cbdMD YCBD	-29.5 K	$ 0.68	0.35 %	$ 2.93 M	USA
OptiNose OPTN	19.5 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	3.13 M	$ 1.01	1.21 %	$ 50.4 M	USA
Solid Biosciences SLDB	824 K	$ 7.89	-1.62 %	$ 690 M	USA
Sonoma Pharmaceuticals SNOA	-10 K	$ 2.38	4.49 %	$ 2.95 M	USA
Zomedica Corp. ZOM	-144 K	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	80.2 K	-	-	$ 55.5 M	USA
Rockwell Medical RMTI	-623 K	$ 0.91	0.05 %	$ 32.7 M	USA
Tricida TCDA	17.6 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	27.3 K	$ 0.65	-	$ 2.79 M	China
TherapeuticsMD TXMD	300 K	$ 2.11	1.69 %	$ 24.4 M	USA